Syros Pharmaceuticals Inc (LTS:0LC7)
$ 0.2 0 (0%) Market Cap: 5.44 Mil Enterprise Value: 7.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 18/100

Syros Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 07:50PM GMT
Release Date Price: $128.6
Aditya Jayanthi

Hi, everyone. Good afternoon. My name is Adi Jayanthi from the JPMorgan Healthcare Investment Banking team. Thank you all very much for being with us this afternoon. It is my pleasure to introduce Nancy Simonian, CEO of Syros Pharmaceuticals. Without further ado, why don't I pass it right over to Nancy.

Nancy A. Simonian
Syros Pharmaceuticals, Inc. - President, CEO & Director

Thanks, Adi. And thanks very much for the invitation to speak. I will be making forward-looking statements for a full list of our risk factors, please see our website.

Next slide. Our vision for Syros is to build a great and enduring company that makes a profound difference for patients. I've worked on a number of successful drugs in my career that had made a big difference for patients with cancer, multiple sclerosis and inflammatory bowel disease. And as an industry, we've made significant progress on a lot of diseases, but many more continue to allude effective treatment. And it was clear to me that we needed to be looking for different approaches to drug

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot